Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2014

01-11-2014 | Preclinical study

Small molecule 1′-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway

Authors: Jieqiong Wang, Li Zhang, Guoliang Chen, Jing Zhang, Zhenxi Li, Weiqiang Lu, Mingyao Liu, Xiufeng Pang

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Login to get access

Abstract

Signal transducer and activator of transcription 3 (STAT3) is implicated breast cancer metastasis and represents a potential target for developing new anti-tumor metastasis drugs. The purpose of this study is to investigate whether the natural agent 1′-acetoxychavicol acetate (ACA), derived from the rhizomes and seeds of Languas galanga, could suppress breast cancer metastasis by targeting STAT3 signaling pathway. ACA was examined for its effects on breast cancer migration/invasion and metastasis using Transwell assays in vitro and breast cancer skeletal metastasis mouse model in vivo (n = 10 mice per group). The inhibitory effect of ACA on cellular STAT3 signaling pathway was investigated by series of biochemistry analysis. The chavicol preferentially suppressed cancer cell migration and invasion, and this activity was superior to its cytotoxic effects. ACA suppressed both constitutive and interleukin-6-inducible STAT3 activation and diminished the accumulation of STAT3 in the nucleus and its DNA-binding activity. More importantly, ACA treatment led to significant up-regulation of Src homology region 2 domain-containing phosphatase 1 (SHP-1), and the ACA-induced depression of cancer cell migration and STAT3 signaling could be apparently reversed by blockade of SHP-1. Matrix metalloproteinase (MMP)-2 and -9, gene products of STAT3 that regulate cell invasion, were specifically suppressed by ACA. In tumor metastasis model, ACA potently inhibited the human breast cancer cell-induced osteolysis, and had little apparent in vivo toxicity at the test concentrations. ACA is a novel drug candidate for the inhibition of tumor metastasis through interference with the SHP-1/STAT3/MMPs signaling pathway.
Literature
1.
2.
3.
4.
Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904PubMedCrossRef
5.
Wang TH, Niu GL, Kortylewski M, Burdelya L, Shain K, Zhang SM, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H (2004) Regulation of the innate and adaptive immune responses by STAT-3 signaling in tumor cells. Nat Med 10(1):48–54PubMedCrossRef
6.
Huang SY (2007) Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13(5):1362–1366PubMedCrossRef
7.
Devarajan E, Huang S (2009) STAT3 as a central regulator of tumor metastases. Curr Mol Med 9(5):626–633PubMedCrossRef
8.
Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10):740–749PubMedCrossRef
9.
Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC (2008) JAK kinases overexpression promotes in vitro cell transformation. Oncogene 27(11):1511–1519PubMedCrossRef
10.
Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T (1996) Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 16(12):6985–6992PubMedCentralPubMed
11.
12.
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S (2004) STAT3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23(20):3550–3560PubMedCrossRef
13.
Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by STAT3-C. Proc Natl Acad Sci USA 101(29):10602–10607PubMedCentralPubMedCrossRef
14.
Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G, Bishayee A (2014) Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta 1845 2:136–154
15.
Pandey MK, Sung B, Aggarwal BB (2010) Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer 127(2):282–292PubMedCentralPubMed
16.
Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G (2011) Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 17(6):1425–1439PubMedCrossRef
17.
Jung JE, Kim HS, Lee CS, Park DH, Kim YN, Lee MJ, Lee JW, Park JW, Kim MS, Ye SK, Chung MH (2007) Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis 28(8):1780–1787PubMedCrossRef
18.
Ohnishi M, Tanaka T, Makita H, Kawamori T, Mori H, Satoh K, Hara A, Murakami A, Ohigashi H, Koshimizu K (1996) Chemopreventive effect of a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate, on rat oral carcinogenesis. Jpn J Cancer Res 87(4):349–356PubMedCrossRef
19.
Murakami A, Ohura S, Nakamura Y, Koshimizu K, Ohigashi H (1996) 1′-Acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin. Oncology 53(5):386–391PubMedCrossRef
20.
Ohata T, Fukuda K, Murakami A, Ohigashi H, Sugimura T, Wakabayashi K (1998) Inhibition by 1′-acetoxychavicol acetate of lipopolysaccharide- and interferon-gamma-induced nitric oxide production through suppression of inducible nitric oxide synthase gene expression in RAW264 cells. Carcinogenesis 19(6):1007–1012PubMedCrossRef
21.
Tanaka T, Kawabata K, Kakumoto M, Makita H, Matsunaga K, Mori H, Satoh K, Hara A, Murakami A, Koshimizu K, Ohigashi H (1997) Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate. Jpn J Cancer Res 88(9):821–830PubMedCrossRef
22.
Kawabata K, Tanaka T, Yamamoto T, Ushida J, Hara A, Murakami A, Koshimizu K, Ohigashi H, Stoner GD, Mori H (2000) Suppression of N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis by dietary feeding of 1′-acetoxychavicol acetate. Jpn J Cancer Res 91(2):148–155PubMedCrossRef
23.
Kato R, Matsui-Yuasa I, Azuma H, Kojima-Yuasa A (2014) The synergistic effect of 1′-acetoxychavicol acetate and sodium butyrate on the death of human hepatocellular carcinoma cells. Chem Biol Interact 212C:1–10CrossRef
24.
Wang H, Shen L, Li X, Sun M (2013) MicroRNAs contribute to the anticancer effect of 1′-acetoxychavicol acetate in human head and neck squamous cell carcinoma cell line HN4. Biosci Biotechnol Biochem 77(12):2348–2355PubMedCrossRef
25.
Williams M, Tietzel I, Quick QA (2013) 1′-Acetoxychavicol acetate promotes caspase 3-activated glioblastoma cell death by overcoming enhanced cytokine expression. Oncol Lett 5(6):1968–1972PubMedCentralPubMed
26.
Moffatt J, Kennedy DO, Kojima A, Hasuma T, Yano Y, Otani S, Murakami A, Koshimizu K, Ohigashi H, Matsui-Yuasa I (2002) Involvement of protein tyrosine phosphorylation and reduction of cellular sulfhydryl groups in cell death induced by 1′-acetoxychavicol acetate in Ehrlich ascites tumor cells. Chem Biol Interact 139(2):215–230PubMedCrossRef
27.
Ito K, Nakazato T, Xian MJ, Yamada T, Hozumi N, Murakami A, Ohigashi H, Ikeda Y, Kizaki M (2005) 1′-acetoxychavicol acetate is a novel nuclear factor kappa B inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 65(10):4417–4424PubMedCrossRef
28.
Ichikawa H, Takada Y, Murakami A, Aggarwal BB (2005) Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappa B-regulated gene products. J Immunol 174(11):7383–7392PubMedCrossRef
29.
Ito K, Nakazato T, Murakami A, Ohigashi H, Ikeda Y, Kizaki M (2005) 1′-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL. Biochem Biophys Res Commun 338(4):1702–1710PubMedCrossRef
30.
Pang X, Zhang L, Lai L, Chen J, Wu Y, Yi Z, Zhang J, Qu W, Aggarwal BB, Liu M (2011) 1′-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway. Carcinogenesis 32(6):904–912PubMedCentralPubMedCrossRef
31.
Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M (2009) Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69(14):5893–5900PubMedCentralPubMedCrossRef
32.
Li C, Yang Z, Zhai C, Qiu W, Li D, Yi Z, Wang L, Tang J, Qian M, Luo J, Liu M (2010) Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappa B signaling pathway. Mol Cancer 9:73–85PubMedCentralPubMedCrossRef
33.
Chen J, Wang J, Lin L, He L, Wu Y, Zhang L, Yi Z, Chen Y, Pang X, Liu M (2012) Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther 11(2):277–287PubMedCrossRef
34.
Franke-Fayard B, Waters AP, Janse CJ (2006) Real-time in vivo imaging of transgenic bioluminescent blood stages of rodent malaria parasites in mice. Nat Protoc 1(1):476–485PubMedCrossRef
35.
36.
Schreiner SJ, Schiavone AP, Smithgall TE (2002) Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 277(47):45680–45687PubMedCrossRef
37.
Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19(21):2548–2556PubMedCrossRef
38.
Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB, Rosen J (1995) Spacing of palindromic half sites as a determinant of selective signal transducers and activators of transcription (STAT) DNA binding and transcriptional activity. Proc Natl Acad Sci USA 92(7):3041–3045PubMedCentralPubMedCrossRef
39.
Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R (2006) Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK + anaplastic large-cell lymphoma. Blood 108(8):2796–2803PubMedCrossRef
40.
Sandur SK, Pandey MK, Sung B, Aggarwal BB (2010) 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol Cancer Res 8(1):107–118PubMedCentralPubMedCrossRef
41.
Wu C, Sun M, Liu L, Zhou GW (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306:1–12PubMedCrossRef
42.
Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L (2007) EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 282(37):26656–26664PubMedCrossRef
43.
Ostman A, Hellberg C, Bohmer FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6(4):307–320PubMedCrossRef
44.
Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G, Aggarwal BB (2007) Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res 13(10):3024–3032PubMedCrossRef
45.
Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R (2014) Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 74(1):125–130PubMedCrossRef
46.
Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278(1):16–27PubMedCrossRef
47.
48.
Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massague J, Kang Y (2009) ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 23(16):1882–1894PubMedCentralPubMedCrossRef
49.
Orita S, Hirose M, Takahashi S, Imaida K, Ito N, Shudo K, Ohigashi H, Murakami A, Shirai T (2004) Modifying effects of 1′-acetoxychavicol acetate (ACA) and the novel synthetic retinoids Re-80, Am-580 and Am-55P in a two-stage carcinogenesis model in female rats. Toxicol Pathol 32(2):250–257PubMedCrossRef
50.
Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY (2007) NF-kappa B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13(1):62–69PubMedCrossRef
Metadata
Title
Small molecule 1′-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway
Authors
Jieqiong Wang
Li Zhang
Guoliang Chen
Jing Zhang
Zhenxi Li
Weiqiang Lu
Mingyao Liu
Xiufeng Pang
Publication date
01-11-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3165-6

Other articles of this Issue 2/2014

Breast Cancer Research and Treatment 2/2014 Go to the issue

Epidemiology

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

Epidemiology

Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers

Erratum

Erratum to: Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells

Preclinical study

Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo

Preclinical study

Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers

Review

Polyamines metabolism and breast cancer: state of the art and perspectives
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits